Neumedicines Inc.
Verified IntelNeumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- 2003
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- 133 North Altadena Drive California Pasadena
- City
- Del Mar
- Region / State
- California
- Postal Code
- 91107
- Country
- United States
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for Neumedicines Inc..